Bouman-Thio E - Search Results

1

A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.

Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P, Bouman-Thio E. Westhovens R, et al. J Rheumatol. 2006 May;33(5):847-53. Epub 2006 Apr 1. J Rheumatol. 2006. PMID: 16583466 Clinical Trial.

2

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE. Zhou H, et al. J Clin Pharmacol. 2007 Mar;47(3):383-96. doi: 10.1177/0091270006298188. J Clin Pharmacol. 2007. PMID: 17322150 Clinical Trial.

3

Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.

van Hartingsveldt B, Nnane IP, Bouman-Thio E, Loza MJ, Piantone A, Davis HM, Petty KJ. van Hartingsveldt B, et al. Among authors: bouman thio e. Br J Clin Pharmacol. 2013 May;75(5):1289-98. doi: 10.1111/j.1365-2125.2012.04477.x. Br J Clin Pharmacol. 2013. PMID: 23043368 Free PMC article. Clinical Trial.

4

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H. Xu Z, et al. Among authors: bouman thio e. Br J Clin Pharmacol. 2011 Aug;72(2):270-81. doi: 10.1111/j.1365-2125.2011.03964.x. Br J Clin Pharmacol. 2011. PMID: 21392075 Free PMC article. Clinical Trial.

5

Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.

Zhu Y, Wang Q, Frederick B, Bouman-Thio E, Marini JC, Keen M, Petty KJ, Davis HM, Zhou H. Zhu Y, et al. Among authors: bouman thio e. Clin Drug Investig. 2013 Apr;33(4):291-301. doi: 10.1007/s40261-013-0072-2. Clin Drug Investig. 2013. PMID: 23512638 Clinical Trial.

6

Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.

Zhuang Y, Lyn S, Lv Y, Xu Z, Bouman-Thio E, Masterson T, Ford JA, Keen M, Petty KJ, Davis HM, Zhou H. Zhuang Y, et al. Among authors: bouman thio e. Clin Drug Investig. 2013 Nov;33(11):795-800. doi: 10.1007/s40261-013-0124-7. Clin Drug Investig. 2013. PMID: 23975656 Clinical Trial.

7

A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.

Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J. Bouman-Thio E, et al. J Clin Pharmacol. 2008 Oct;48(10):1197-207. doi: 10.1177/0091270008322907. J Clin Pharmacol. 2008. PMID: 18812609 Clinical Trial.

8

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.

Zhuang Y, Calderon C, Marciniak SJ Jr, Bouman-Thio E, Szapary P, Yang TY, Schantz A, Davis HM, Zhou H, Xu Z. Zhuang Y, et al. Among authors: bouman thio e. Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310. doi: 10.1007/s00228-016-2110-5. Epub 2016 Aug 11. Eur J Clin Pharmacol. 2016. PMID: 27515978 Clinical Trial.

9

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.

Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, Marini JC, Keen M, Snead D, Davis HM, Zhou H. Xu Z, et al. Among authors: bouman thio e. J Clin Pharmacol. 2010 Mar;50(3):276-84. doi: 10.1177/0091270009340782. Epub 2009 Nov 25. J Clin Pharmacol. 2010. PMID: 19940229 Clinical Trial.

10

Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects.

Ling J, Lyn S, Xu Z, Achira M, Bouman-Thio E, Shishido A, Ford J, Shankar G, Wagner C, Kim KT, Davis HM, Zhou H. Ling J, et al. Among authors: bouman thio e. J Clin Pharmacol. 2010 Jul;50(7):792-802. doi: 10.1177/0091270009355162. Epub 2010 Feb 4. J Clin Pharmacol. 2010. PMID: 20133508 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters